Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOL-R: OTX-TKI vs Aflibercept in nAMD
NCT06495918Phase 3Active, not recruiting
- Sponsor
- Ocular Therapeutix
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of axitinib in neovascular age-related macular degeneration (NVAMD), sponsored by Ocular Therapeutix. Primary endpoint: Best Corrected Visual Acuity at Week 48. Started Nov 2024; status: active, not recruiting.
02
Drugs
axitinib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06495918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495918.